Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

Rhea-AI Summary

Mineralys Therapeutics (NASDAQ: MLYS) has scheduled a conference call and webinar for March 10, 2025, at 8:00 AM ET to announce topline results from two pivotal trials: Launch-HTN and Advance-HTN.

The trials evaluated lorundrostat, a highly selective aldosterone inhibitor, for treating uncontrolled hypertension (uHTN) or resistant hypertension (rHTN). The Launch-HTN trial tested lorundrostat as an add-on therapy to existing prescribed background treatment of 2-5 antihypertensive medications, while Advance-HTN evaluated it as an add-on to a standardized background treatment of 2-3 anti-hypertensive medications.

News Market Reaction

+42.21%

1 alert

+42.21% News Effect

On the day this news was published, MLYS gained 42.21%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

RADNOR, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will host a conference call and webinar to announce topline results from its Launch-HTN and Advance-HTN pivotal trials on Monday, March 10, 2025, at 8:00 a.m. ET.

The Launch-HTN trial evaluated the efficacy and safety of lorundrostat, a highly selective aldosterone inhibitor, for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) as an add-on therapy to an existing, prescribed background treatment of two to five antihypertensive medications.

The Advance-HTN trial evaluated the efficacy and safety of lorundrostat for the treatment of uHTN or rHTN when used as an add-on therapy to a standardized background treatment of two or three anti-hypertensive medications.

Monday, March 10th@ 8:00 a.m. ET
Domestic:	1-877-704-4453
International:	1-201-389-0920
Webcast:	Link

A live webcast of the conference call may also be found on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.

About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.

Contact:

Investor Relations
investorrelations@mineralystx.com

Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com

FAQ

When will Mineralys Therapeutics (MLYS) announce the Launch-HTN and Advance-HTN trial results?

Mineralys will announce the results on Monday, March 10, 2025, at 8:00 AM ET via a conference call and webinar.

What is the purpose of the Launch-HTN trial for MLYS's lorundrostat?

Launch-HTN evaluates lorundrostat as an add-on therapy to 2-5 existing antihypertensive medications for uncontrolled or resistant hypertension.

How does the Advance-HTN trial differ from Launch-HTN for MLYS's hypertension treatment?

Advance-HTN tests lorundrostat with a standardized background of 2-3 anti-hypertensive medications, while Launch-HTN uses 2-5 existing prescribed medications.

What conditions is Mineralys Therapeutics (MLYS) targeting with lorundrostat?

MLYS is targeting hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and other diseases driven by dysregulated aldosterone.